# US 2026/0015322 A1 · Delivery of therapeutic alkaloid compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0015322 A1
- Document ID: US20260015322A1
- Status: Published application
- Kind: A1
- Application number: 18/995,408
- Filed: 2023-07-28
- Published: 2026-01-15
- Earliest claimed: 2022-07-29
- Assignees: Sensorium Therapeutics, Inc.
- Applicants: Sensorium Therapeutics, Inc.
- Inventors: Jacob M. Hooker; Michael S. Placzek
- Web page: https://patentgrep.com/patent/US20260015322A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65742: {non-condensed with carbocyclic rings or heterocyclic rings or ring systems}
- C07F 9/65744: {condensed with carbocyclic or heterocyclic rings or ring systems}
- C07F 9/6584: having one phosphorus atom as ring hetero atom
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds that can be converted to mesembrine under physiologically relevant conditions, and related methods of preparing and using the compounds.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C7 alkyl;
ring A is
wherein * denotes the attachment points of ring A to the compound of formula (I),
R2 is —C(O)NR3R4, —C(O)OR6, or —P(O)OR4OR5;
R3 is H, C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, C1-C3 alkyl-C3-C10 cycloalkyl, phenyl, or 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, phenyl, and 5- to 7-membered heteroaryl is optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy;
R4 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl;
or R3 and R4 combine to form a 4- to 7-membered heterocycle, wherein each hydrogen atom in the 4- to 7-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, phenyl, 5- to 7-membered heterocycle, 5- to 7-membered heteroaryl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy;
R5 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl;
or R4 and R5 combine to form a 4- to 8-membered heterocycle, wherein each hydrogen atom in the 4- to 8-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, phenyl, 5- to 7-membered heterocycle, 5- to 7-membered heteroaryl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy;
R6 is C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, C1-C3 alkyl-C3-C10 cycloalkyl, phenyl, or 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, phenyl, and 5- to 7-membered heteroaryl is optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy; and
n is 1 or 2.

### Claim 39 (depends on 38)

The compound of claim 38, wherein Rt is methyl.

### Claim 40 (depends on 39)

The compound of claim 39, wherein R2 is —C(O)NR3R4.

### Claim 41 (depends on 40)

The compound of claim 40, wherein:
a. R3 and R4 are each independently H or C1-C6 alkyl;
b. R3 is phenyl optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy; and R4 is H or C1-C6 alkyl; or
c. R3 and R4 combine to form a 4- to 7-membered heterocycle, wherein each hydrogen atom in the 4- to 7-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, phenyl, 5- to 7-membered heterocycle, 5- to 7-membered heteroaryl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, or cyano; or
d. R3 is C3-C10 cycloalkyl optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy; and R4 is H or C1-C6 alkyl; or
e. R3 is C3-C10 cycloalkyl optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, or cyano; and R4 is H or C1-C6 alkyl; or
f. R3 is C1-C6 alkyl optionally substituted by C1-C3 alkoxy, or —COOH; and R4 is H or C1-C6 alkyl.

### Claim 42 (depends on 38)

The compound of claim 38, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 39)

The compound of claim 39, wherein R2 is-C(O)OR6.

### Claim 44 (depends on 43)

The compound of claim 43, wherein R6 is C1-C6 alkyl.

### Claim 45 (depends on 43)

The compound of claim 43, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 39)

The compound of claim 39, wherein R2 is —P(O)OR4OR5.

### Claim 47 (depends on 46)

The compound of claim 46, wherein
b. R4 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl; and
b. R5 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl.

### Claim 48 (depends on 46)

The compound of claim 46, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 46)

The compound of claim 46, wherein R4 and R5 combine to form a 4- to 8-membered heterocycle, wherein each hydrogen atom in the 4- to 8-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, phenyl, 5- to 7-membered heterocycle, 5- to 7-membered heteroaryl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy.

### Claim 50 (depends on 46)

The compound of claim 46, wherein R2 is

### Claim 51 (depends on 46)

The compound of claim 46, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 46)

The compound of claim 46, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 46)

The compound of claim 46, wherein the compound is
or
a pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 38)

The compound of claim 38, wherein the compound is of formula (I-A):
or a pharmaceutically acceptable salt thereof, wherein the compound has the absolute stereochemistry shown.

### Claim 55 (depends on 54)

The compound of claim 54, wherein
R1 is methyl;
ring A is
wherein * denotes the attachment points of ring A to the compound of formula (I-A),
R2 is —C(O)NR3R4, —C(O)OR6, or —P(O)OR4OR5; and
R3 is H, C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, C1-C3 alkyl-C3-C10 cycloalkyl, phenyl, or 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, phenyl, and 5- to 7-membered heteroaryl is optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, or cyano; and
R4 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl; or
R3 and R4 combine to form a 4- to 7-membered heterocycle, wherein each hydrogen atom in the 4- to 7-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, or cyano; and
R5 is H, C1-C6 alkyl, phenyl, —(CH2O)n—C(O)OC1-C6 alkyl, or —(CH2O)n—C(O)C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is optionally substituted by phenyl;
or R4 and R5 combine to form a 4- to 8-membered heterocycle, wherein each hydrogen atom in the 4- to 8-membered heterocycle is optionally substituted by halo, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C3-C10 cycloalkyl, phenyl, 5- to 7-membered heterocycle, 5- to 7-membered heteroaryl, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy; and
R6 is C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, C1-C3 alkyl-C3-C10 cycloalkyl, phenyl, or 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, phenyl, and 5- to 7-membered heteroaryl is optionally substituted by halo, hydroxy, C1-C6 alkyl, C1-C3 alkoxy, nitro, —N(C1-C3 alkyl)2, —NH2, —N(H)C1-C3 alkyl, C1-C3 haloalkyl, —COOH, cyano, phenyl, or phenoxy; and
n is 1 or 2.

### Claim 56 (depends on 38)

A pharmaceutical composition, comprising a compound of claim 38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 57 (depends on 38)

A method of treating a mental health disorder, comprising administering to a mammal in need thereof an effective amount of a compound of claim 38, or a pharmaceutically acceptable salt thereof; wherein the mental health disorder is anxiety, stress, or depression.
